Introduction

Regulatory T (Treg) cells play critical roles in maintaining immune homeostasis. Treg cells inhibit differentiation and proliferation of conventional T (Tconv) cells including Th1, Th2, Th17 and Tfh cells. Treg cells thereby prevent excessive immune responses against self-antigens, food antigens, commensal microorganisms and cancers1,2,3. Treg cells can develop either in the thymus (tTreg) or by differentiation from naïve CD4 T cells in the periphery (pTreg).

Foxp3, an X-chromosome-encoded member of the Forkhead family, is the lineage-determining transcription factor for Treg cells2,3,4. Foxp3 is involved in the control of differentiation and function of Treg cells. Loss of Foxp3 function causes the fatal autoimmune disease immune dysregulation, polyendocrinopathy, enteropathy, X-linked in humans and mice5,6,7. Ectopic expression of Foxp3 in CD4+CD25 T cells confers suppressive function and induces expression of Treg cell signature genes including Cd25, Ctla4, Icos and Gitr8,9. Furthermore, sustained Foxp3 expression is essential for maintenance of the Treg-cell phenotype and associated functions1,10. Deficiency of Foxp3 expression in Treg cells causes both defective function of Treg cells and the acquisition of Tconv-cell properties5,6,7. Taken together, these previous studies show that Foxp3 is indispensable for the differentiation and function of Treg cells, specifying the Treg cell lineage.

Understanding the positive and negative regulation of Foxp3 is critically important in controlling Treg cell-regulated immune responses, including those involved in autoimmune diseases, allergies, organ transplantation and cancer7. For example, upregulation of Treg function is likely to be beneficial for autoimmune diseases, allergy and organ transplantation. By contrast, downregulation of Treg function could enhance protective immunity against infectious agents and cancer7.

A number of transcription factors play roles in the induction of Foxp3 and downstream signalling pathways by TCR/CD28 stimulation. For example, at the Foxp3 locus, NFAT, AP1, SP1 and c-Rel bind to the promoter; AP1 and NFAT bind conserved non-coding sequence 1 (CNS1); CREB and ATF bind to CNS2 and c-Rel binds to CNS3 in response to TCR/CD28 activation3,11,12. interleukin (IL)-2 signalling is important for the induction of Foxp3 gene by STAT5, which binds to the promoter and CNS2 of the Foxp3 locus3,11,12. Transforming growth factor (TGF)-β also plays a crucial role in the induction of the Foxp3 gene. Following TGF-β-induced phosphorylation of Smad3 and its dimerization with Smad4, the heterodimer translocates into the nucleus and binds to CNS1 to induce Foxp3 gene expression3,4,11,12. Other transcription factors including Foxo1, Foxo3, Runx1, Runx3, RXR/RAR and Notch1 were also shown to be involved in the induction of Foxp3 expression3,11,13.

Compared with a large number of positive regulators of Foxp3, only a few negative regulators of Foxp3 are known until now. GATA3, a crucial regulator of Th2 differentiation, binds to the Foxp3 promoter and represses Foxp3 expression during Th2 differentiation12,14. In addition, STAT3 competes with STAT5 to bind to the Foxp3 promoter and CNS2, and represses Foxp3 expression in response to IL-6 (refs 12, 15). Furthermore, RORγt directly binds to the Foxp3 promoter and causes loss of Foxp3 expression during Th17 differentiation16.

YY1, encoded by Yy1, is a transcription factor that functions either as an activator or repressor depending on the chromatin context17,18,19. YY1 interacts with many factors including transcription factors, co-activators and co-repressors. Previous studies show that YY1 has pleiotropic effects on many different cellular processes, including cell growth and differentiation, apoptosis, development and tumorigenesis17,18,19,20. Th2-cell differentiation also involves YY1 (refs 21, 22), which mediates chromatin remodelling and chromosomal looping of the Th2 cytokine locus to regulate Th2 cytokine genes23. However, the roles of YY1 in Treg-cell function have not been investigated.

In the present study, the role of YY1 on Treg-cell differentiation and function was examined. YY1 was selectively downregulated in Treg cells, and YY1 overexpression caused a reduction of Foxp3 expression and a loss of suppressive function during Treg differentiation. YY1 inhibited induction of the Foxp3 gene by impeding the TGF-β-Smad3/4 signalling pathway. Moreover, YY1 physically interacted with Foxp3 and blocked Foxp3-target genes. These results strongly suggest that YY1 inhibits the differentiation and function of Treg cells by blocking expression of Foxp3 and its target genes.

Results

YY1 is expressed at low levels in Treg cells

Previous studies identified YY1 as a protein-binding partner24 of and the Yy1 locus as a cis-target (binding site) of Foxp3 (refs 24, 25, 26). The role of YY1 in Treg-cell differentiation was of particular interest because YY1 expression was selectively low in induced Treg cells compared with in vitro-differentiated conventional T (Tconv) cells (Fig. 1a,b). The expression of YY1 in CD4 T cells isolated from the mouse thymus, spleen and peripheral and mesenteric lymph nodes was then studied. YY1 expression levels were lower in CD4+CD25+ Treg cells than in CD4+CD25 Tconv cells from all the lymphoid tissues examined (Fig. 1b–d). The expression levels of YY1 were also investigated in enriched CD4 T cells using Foxp3-eGFP reporter mice (Fig. 1e). The majority of YY1-expressing cells were non-Treg (CD4+GFP) cells (Fig. 1e). Yy1 expression was high in effector/memory CD4 T cells, but low in Treg and naïve CD4 T cells (Fig. 1f).

Figure 1: Expression of YY1 is low in Treg cells.
figure 1

(a) Naïve CD4 T cells from WT mice were differentiated into Th0, Th1, Th2 and Treg cells for 5 days. Relative amount of Yy1 transcript was measured by qRT–PCR. (b) Relative amounts of YY1 protein in in vitro-differentiated CD4 T cells or splenic Tconv (CD4+CD25) and Treg (CD4+CD25+) cells were measured by immunoblot analysis. (c) Relative amounts of Yy1 transcript in Tconv and Treg cells in axillary (aLN), cervical (cLN), inguinal (iLN) and mesenteric (mLN) lymph nodes and spleen (spl) were detected by qRT–PCR. (d) Amounts of YY1 protein in Tconv or Treg cells were measured using flow cytometry. IgG: isotype control. (e) CD4 cells were enriched from splenocytes of Foxp3-eGFP mice, and then YY1 underwent intracellular staining. The percentage of YY1+ cells from CD4+GFP+(Treg) and CD4+GFP(non-Treg) were shown (left), the percentage of Treg (GFP+) and non-Treg (GFP) from YY1+ cells were shown (centre) and the FACS plot is shown (right). (f) CD4 T cells from Foxp3-eGFP mice were stained with CD62L antibody. Naïve, effector and Treg cells were sorted (left) and relative amounts of Yy1 transcript were measured by qRT–PCR (right). (g) Control GFP vector or Foxp3 expression vector was transduced into Th0 cells. After 4 days, YY1 protein was detected by flow cytometry. IgG: isotype control. (h) GFP+ cells from g were isolated, and relative amounts of Yy1 and Foxp3 transcripts were measured using qRT–PCR. (i) WT naïve CD4 T cells were transduced with GFP containing control or sh-Foxp3 vectors and differentiated into Treg cells for 4 days. Relative amounts of Yy1 and Foxp3 transcripts were measured using qRT–PCR. (j) Binding of Foxp3 to two YY1 promoter regions was detected by EMSA using Tconv and Treg nuclear extracts with forkhead consensus sequence (x80). Arrows indicate Foxp3-DNA complexes. (kl) Binding of Foxp3 (k) and H3K4me1 (l) in Treg or Tconv cells was measured by ChIP assay. Error bars shown in (a), (c), (f), (h), (k) and (l) represent s.d. Statistical differences in (a), (c), (f), (h), (k) and (l) were analysed by Student’s t-test (n=3). *P<0.05, **P<0.01. Experiments were performed at least three times with similar results.

Influence of Foxp3 on YY1 expression

To examine whether the low expression of YY1 in Treg cells is caused by Foxp3, overexpression or knockdown (KD) of Foxp3 was used. When murine Th0 cells were transduced with a Foxp3 overexpression vector (MIEG3-Foxp3) and then cultured for 4 days, levels of YY1 decreased (Fig. 1g,h). Whereas when the cells were transduced with a Foxp3 KD vector (sh-Foxp3) and then cultured for 4 days, the levels of YY1 increased (Fig. 1i). Electrophoresis mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assays using Treg and Tconv cells showed that Foxp3 directly bound to the promoter of the Yy1 gene in Treg cells (Fig. 1j,k), which is consistent with previous Foxp3 ChIP-seq data24,25,26. Two possible Foxp3-binding sites in the promoter are shown in Supplementary Fig. 1. In addition, Histone H3 lysine 4 monomethylation (H3K4me1), a marker for active chromatin, was reduced at the promoter of the Yy1 gene in Treg cells compared with Tconv cells (Fig. 1l). These results suggest that Foxp3 represses the induction of YY1 in Treg cells.

YY1 inhibits expression of Foxp3 and Treg signature markers

To examine the role of YY1 during Treg differentiation, YY1 was introduced into naïve murine CD4 T cells that were then subjected to Treg differentiation conditions. Foxp3 expression was markedly decreased in YY1-transduced Treg cells compared with those in control vector-transduced Treg cells (Fig. 2a–c). Furthermore, Treg signature genes including Il10, Cd25, Ctla4, Gitr and Icos, but not unrelated genes including Ifng, Il2 and Il17, were also decreased in YY1-transduced Treg cells (Fig. 2d). To get an insight of changes in global gene expression patterns by YY1 expression in Treg cells, a microarray analysis was performed with RNA isolated from cells transduced with control or YY1-expression vector and differentiated into iTreg cells (Supplementary Fig. 2 and Supplementary data; Gene Expression Omnibus (GEO) accession number GSE75052). Overall, among genes changed more than twofold by YY1 overexpression, we found that more genes were upregulated than were downregulated, except genes related to immune responses or inflammatory responses (Supplementary Fig. 2A), suggesting that YY1 enhances general cellular activities. In the category of genes related to Treg-cell differentiation, more genes were downregulated than were upregulated by YY1 overexpression (Supplementary Fig. 2B), consistent with our quantitative reverse transcription–PCR (qRT–PCR) data (Fig. 2c,d). Proliferation and cell death of YY1-transduced Th0 and Treg cells were examined using anti-Ki-67 antibody and Annexin V, respectively. Overexpression of YY1 did not affect proliferation or apoptosis in either Th0 or Treg cells (Fig. 2e,f). These data indicate that decreased Foxp3 expression in YY1-transduced Treg cells is not due to proliferation or apoptosis of these cells. To examine whether deficiency influences Treg differentiation, naïve CD4 T cells from floxed YY1 (YY1 fl/fl) mice were transduced with retroviral Cre-expression vector (RV-Cre). YY1 deficiency did not influence either the expression of Foxp3 or proliferation and cell death during Treg-cell differentiation (Fig. 3a–d). Treg populations in the spleen or peripheral lymph nodes of YY1 KD mice23 were not different from those of wild-type (WT) mice (Fig. 3e), suggesting that YY1 KD does not affect Foxp3 expression in Treg cells in vivo. Taken together, these data suggest that YY1 inhibits but does not enhance expression of Foxp3 and Treg signature genes in Treg cells.

Figure 2: YY1 overexpression causes a loss of Foxp3 and Treg signature genes.
figure 2

(a) WT naïve CD4 T cells were transduced with retroviral vector containing GFP or Yy1 and differentiated into Treg cells for 4 days. Expression of Foxp3 was measured by flow cytometry (left), and the ratio of Foxp3+ cells in GFP+ cells was shown (right). (b) Immunoblot analysis of YY1 and Foxp3 from GFP+ cells. (c,d) GFP+ cells from a were sorted, and total RNA was isolated. Relative amounts of the Foxp3 and Yy1 (c) and Treg signature genes (d) were measured by qRT–PCR. (e) Proliferation of control or YY1-transduced Th0 or Treg cells was measured using Ki-67 antibody. Cells were gated on GFP+ expression. (f) Apoptosis of control or YY1-transduced Th0 or Treg cells was analysed by Annexin V staining. Experiments were performed three times with similar results. Statistical differences in a and d were analysed by Student’s t-test (n=3). *P<0.05; **P<0.01. Error bars shown in a and d represent s.d.

Figure 3: YY1 deficiency does not influence Foxp3 expression.
figure 3

(a) Naïve CD4 T cells from YY1 fl/fl mice were transduced with either control vector or CRE-expressing vector (RV-Cre) and cultured under the Treg differentiation condition for 4 days. Foxp3 was stained and measured by flow cytometry. Numbers in the FACS plots indicate the percentage of Foxp3+ cells from GFP+ cells. (b) GFP+ cells from a were sorted, and total RNA was isolated. A relative amount of Foxp3 was measured by qRT–PCR. (c) Proliferation of YY1-deficient Treg cells was detected with Ki-67 staining from GFP+ cells. (d) Apoptosis of YY1-deficient Treg cells was measured with Annexin V staining. Experiments were performed five times with similar results. (e) Treg populations in the spleen and peripheral lymph nodes of YY1 KD or WT mice were analysed by staining anti-CD4, anti-CD25 and anti-Foxp3. Cells were gated on CD4.

YY1 inhibits suppressive functions of Treg cells

To examine whether YY1 affects the function of Treg cells, in vitro immunosuppression assays were performed. tTreg cells were isolated from Foxp3-RFP knock-in mice27 based on red fluorescent protein (RFP) expression and transduced with either control or YY1 expression vector. Murine CD45.1+ CD4+CD25 responder T (Tresp) cells stained with carboxyfluorescein succinimidyl ester (CFSE), a fluorescent dye, were mixed with various ratios of control or YY1-overexpressing tTreg cells and incubated for 3 days in the presence of anti-CD3/anti-CD28 beads. Proliferation was measured on CD45.1+ (Tresp) cells. YY1-overexpressing tTreg cells had weaker suppressive function in proliferation of Tresp cells as the ratio increases than control tTreg cells did (Fig. 4a). Next, the role of YY1 in Treg cell function in vivo was examined using an animal model of inflammatory bowel disease. CD4+CD62L+CD45RB+ naïve CD4 T cells were adoptively transferred, alone or in combination with control tTreg cells or YY1-overexpressing tTreg cells prepared as described above, into RAG1-deficient mice. As expected, transfer of naïve CD4 T cells alone caused severe colitis characterized by gradual weight loss (Fig. 4b), inflammation in the colonic mucosa, splenomegaly and shortened colon length (Fig. 4c,d). The mice also had an increased total number of splenocytes and CD4 T cells (Fig. 4e), a greater frequency of effector CD4 T cells (Fig. 4f and Supplementary Fig. 3), and a low frequency of Foxp3+ cells (Fig. 4g) in the spleen. Transfer of naïve CD4 T cells with control tTreg cells completely suppressed the inflammatory phenotypes; however, the transfer of naïve CD4 T cells with YY1-overexpressing tTreg cells failed to suppress the inflammatory phenotypes (Fig. 4b–g). Adoptively transferred YY1-overexpressing tTreg cells could not inhibit differentiation of the co-transferred naïve CD4 T cells into pathogenic Th1 and Th17 cells, and could not increase their cell number (Fig. 4f,g), suggesting that these tTreg cells are functionally impaired in this experimental setting. The numbers of YY1-transduced tTreg cells recovered in the spleen of the recipient mice were similar to those of control tTreg cells (Fig. 4h), suggesting that the observed phenotypes are not due to poor survival of the YY1-transduced tTreg cells in the mice. Taken together, these data suggest that YY1 inhibits the suppressive function of Treg cells both in vitro and in vivo.

Figure 4: YY1 impairs immunosuppressive function of tTreg cells in vitro and in vivo.
figure 4

(a) In vitro immunosuppressive activity of tTreg cells was assessed by proliferation of CD4+CD25 Tresp cells (labelled with CFSE from CD45.1+ Tresp cells). Foxp3+ Treg cells were isolated from Foxp3-RFP knock-in mice and transduced with control or YY1-expression vector. GFP+ control tTreg (tTreg(ctrl)) or GFP+ YY1-overexpressing tTreg (tTreg(YY1)) cells were sorted, mixed with CD4 Tresp cells in various ratios, and cultured in the presence of anti-CD3/CD28 beads for 3 days. Proliferation was measured on CD45.1+ (Tresp) cells. (bh) In vivo immunosuppressive activity of tTreg cells was assessed by inflammatory bowel disease model. tTreg (ctrl) and tTreg (YY1) cells were prepared as in a from Foxp3-RFP knock-in mice. Naïve CD4 T (CD4+CD25CD62L+CD45RBhigh) cells alone or together with tTreg (ctrl) or tTreg (YY1) cells were adoptively transferred into RAG1−/− mice. The mice were killed at 12 weeks after the cell transfer, and analysed for disease phenotypes. (b) Body weight of the recipient mice was presented as a percentage of the initial weight. (c) Gross morphology of colons and spleens. (d) Haematoxylin and eosin staining of colon sections. Scale bar indicates 200 μm. (e) Absolute numbers of splenocytes and splenic CD4 T cells. (f) Frequency of cytokine-producing effector CD4 T cells in the spleen. (g) Absolute numbers of CD4+Foxp3+ cells from the spleen. (h) Absolute numbers of GFP+ tTreg cells from the spleen. Error bars shown in bh represent s.d. Statistical differences in bh were analysed by Student’s t-test (n=5). *P<0.05. **P<0.01. NS, not significant.

YY1 expression is modulated under inflammatory conditions

It has been shown that Treg cell’s functional properties can be changed under inflammatory conditions28,29,30. To further investigate physiological relevance of YY1 expression in Treg cells, we examined whether YY1 expression is modulated in Treg cells under an inflammatory condition using dextran sodium sulfate (DSS)-induced colitis model. 5% DSS in drinking water was administered into C57BL/6 mice for 4 days, and the mice were killed at day 7. As was well known, DSS-treated mice had decreased body weights, increased cell infiltration into the colon and shortened colon length (Fig. 5a–c), showing an inflammatory condition in the colon. Cellular RNA was extracted from the colons of the mice and expressions of Ifng and Il17 were measured by qRT–PCR. DSS-treated mice had highly increased Ifng and Il17 (Fig. 5d), showing that inflammatory Th1 and Th17 responses were developed in these mice. Under this condition, the frequencies of YY1-expressing Treg cells were increased in the spleen, mesenteric lymph node and peripheral lymph node in DSS-treated mice compared with those in control mice (Fig. 5e). Treg and Tconv cells were isolated from the mice and expression of the Foxp3, Yy1, Ifng and Il17 transcript was measured by qRT–PCR. Consistent with pathogenic inflammatory condition, expression of Ifng and Il17 was increased in DSS-treated Tconv cells (Fig. 5f,g). Expression of Yy1 was increased in DSS-treated Treg cells concomitant with decreased Foxp3 expression (Fig. 5h,i). This result suggests that YY1 expression is modulated under inflammatory condition under which Treg-cell functions are modulated.

Figure 5: YY1 expression is enhanced in inflammatory condition in vivo.
figure 5

WT mice were introduced with water or 5% dextran sodium sulfate (DSS) for 4 days to induce IBD. The mice were killed at 7 days after DSS administration, and analysed for disease phenotypes. (a) Body weights of the mice were presented as a percentage of the initial weight. (b) Haematoxylin and eosin staining of colon sections. Scale bar indicates 200 μm. (c) Gross morphology of colons (left) and colon length (right). (d) Colonic RNA was isolated, and relative amounts of Ifng and ll17 transcripts were measured by qRT–PCR. (ei) Tconv and Treg cells were isolated from the spleen (spl), mesenteric lymph node (mLN) and peripheral lymph node (pLN). Protein levels of YY1 and Foxp3 were measured by intracellular staining (e). Total RNA was extracted, and transcripts of Ifng (f), Il17 (g), Foxp3 (h) and Yy1 (i) were measured by qRT–PCR. Statistical differences in ai were analysed by Student’s t-test (n=5). *P<0.05. **P<0.01. ***P<0.001. Error bars shown in ai represent s.d.

YY1 inhibits Foxp3 expression by blocking Smad3/Smad4

Foxp3 is induced by the TGF-β signalling pathway, and Smad3 and Smad4 are essential transcription factors for the induction of the Foxp3 gene in this pathway. Upon TGF-β stimulation, the Smad3/4 heterodimer directly binds to the Foxp3 CNS1, which contains a Smad-binding element (SBE) as a TGF-β sensor4. To investigate molecular mechanisms for YY1-mediated Foxp3 regulation, we first examined whether YY1 interacts with Smad3 and Smad4 by co-immunoprecipitation (co-IP) experiments. YY1 was co-immunoprecipitated with Smad3 and Smad4 (Fig. 6a), consistent with a previous study31, suggesting that YY1 physically interacts with both Smad3 and Smad4.

Figure 6: YY1 inhibits expression of Foxp3.
figure 6

(a) HEK293T cells were transfected with Smad3-, Smad4- or Yy1-expression vector. Cell lysates were immunoprecipitated with an anti-Smad3, anti-Smad4, anti-YY1 or control IgG antibody. Then, proteins were immunoblotted with an anti-Smad3, anti-Smad4 or anti-YY1 antibody. IP, immunoprecipitation; WB, immunoblot. (b) Binding of Smad3 and Smad4 to the Foxp3 CNS1 in control or YY1-expressing Treg cells was measured by ChIP assay. (c) Binding of Foxp3 to Smad-binding element (SBE) in the Foxp3 CNS1 was detected by EMSA using control or YY1-expressing Treg nuclear extracts. Competition assay was performed with Smas3/4 consensus sequence (x80). Arrows indicate Smad3/4-SBE complexes. (d) Nuclear extracts overexpressing Smad3 and Smad4 with increasing amounts of YY1 were mixed with SBE of the Foxp3 CNS1, and DNA pull-down assay were performed. Oligo-dT was used as a negative control. (e) Transactivation activity of the Foxp3 promoter by Smad3 and YY1 was measured by transient reporter assay. EL4 cells were transfected with Foxp3 promoter-CNS1-luc reporter construct in the absence or presence of Smad3D- (constitutively active form of Smad3) and/or Yy1-expression vector. I, ionomycin; NT, no treatment; P, phorbol 12-myristate 13-acetate. (f) Nuclear extract (N/E) and cytosolic extract (C/E) were isolated from control Treg cells or YY1-transduced Treg cells. Relative amounts of YY1, Smad3, pSmad3 and Smad4 in N/E and C/E were measured by immunoblot analysis. β-Actin and Lamin were used as loading controls. Statistical differences in b,d and e were analysed by Student’s t-test (n=3). *P<0.05. **P<0.01. ***P<0.001. Error bars shown in b,d and e represent s.d.

To test whether YY1 interferes with the binding of Smad3 or Smad4 to the Foxp3 CNS1, ChIP assays were performed using a Smad3 or Smad4 antibody in control Treg cells and YY1-transduced Treg cells. Smad3 and Smad4 binding was greatly reduced in YY1-overexpressing Treg cells compared with that in control Treg cells (Fig. 6b). Similar results were obtained with EMSA and DNA pull-down assays, further supporting the possibility that YY1 impedes the binding of Smad3/4 to the SBE in the Foxp3 CNS1 (Fig. 6c,d).

To examine whether YY1 inhibits transactivation of the Foxp3 genes by Smad3, transient reporter assays were performed. EL4 cells were transfected with a reporter construct containing Foxp3 promoter linked with CNS1 along with expression vectors of YY1 or Smad3D (constitutively active form of Smad3). As shown previously4, Smad3D transactivated the Foxp3 gene because of the TGF-β sensor located in CNS1. Interestingly, YY1 completely reduced the transactivation of Foxp3 gene even in the presence of Smad3D (Fig. 6e). However, YY1 did not affect heterodimerization of Smad3/4 (Supplementary Fig. 4), expression of Smad3, phospho-Smad3 and Smad4 (Fig. 2c), and nuclear translocation of Smad3/4 complexes (Fig. 6f). Taken together, these data strongly suggest that YY1 inhibits Foxp3 expression by blocking binding of Smad3/4 to the SBE in the Foxp3 CNS1.

YY1 binds to and represses the Foxp3 locus

The possibility that YY1 may directly bind to the Foxp3 locus to repress its expression was tested. Several putative YY1-binding sites were identified within the Foxp3 locus by transcription factor-binding site analysis (Supplementary Fig. 1). EMSA and ChIP assay in YY1-overexpressing Treg cells confirmed that YY1 directly bound to several regulatory elements at the Foxp3 locus, including the promoter, CNS1 and CNS2 (Fig. 7a,b). YY1 directly bound to the promoter of the Foxp3 gene in Tconv cells but not in Treg cells (Fig. 7c). Transient reporter assays showed that YY1 inhibited transactivation of the Foxp3 gene through binding to the Foxp3 promoter (Fig. 7d).

Figure 7: YY1 represses chromatin modification in the Foxp3 locus.
figure 7

(a) Binding of YY1 to YY1-binding sites (YBS) in the Foxp3 promoter (YBS2), CNS1 (YBS4), CNS2 (YBS7) was measured by EMSA using control or YY1-expressing Treg nuclear extracts. Competition assay was performed with YY1 consensus sequence (x160), and supershift assay was performed with an anti-YY1 antibody. (b) Binding of YY1-Flag to the Foxp3 locus in control or YY1-Flag-expressing Treg cells was measured by ChIP assay. β-Globin region was used as a negative-binding site. (c) Binding of YY1 to the Foxp3 promoter in Treg or Tconv cells was analysed by ChIP assay. (d) Transactivation activity of the Foxp3 promoter by YY1 was detected by transient reporter assay. EL4 cells were transfected with Foxp3 promoter-luc reporter construct and YY1-expression vector. I, ionomycin; NT, no treatment; P, phorbol 12-myristate 13-acetate. (e) Binding of H3-K4-trimethylation or H3 acetylation to the Foxp3 locus was measured by ChIP assay. β-Globin region was used as a negative-binding site. Values of isotype-matched control IgG were subtracted. Statistical significance of differences from be was determined by Student’s t-test (n=3). *P<0.05. **P<0.01. Data are representative of three independent experiments with similar results. Error bars shown in be represent s.d.

Chromatin status was investigated in the Foxp3 locus in control or YY1-overexpressing Treg cells using ChIP assays with anti-H3 acetylation and H3-K4-me3 antibodies. YY1 caused a repressed chromatin status at the Foxp3 locus (Fig. 7e). Taken together, these data suggest that, when overexpressed, YY1 binds physically to the Foxp3 locus, inhibits Foxp3 expression and causes a repressive chromatin status at the locus.

YY1 directly inhibits the expression of Foxp3-target genes

Foxp3 directly binds to and regulates many Treg signature genes, including Cd25, Icos, Ctla4, Gitr and Il10 (refs 25, 26, 32, 33, 34). To test whether YY1 affects this process, the interaction between YY1 and Foxp3 was first examined. Co-IP experiments showed that these proteins interacted with each other (Fig. 8a). Transient reporter assays were then used to examine whether YY1 inhibits transactivation of Foxp3-target genes. EL4 cells were transfected with reporter constructs containing a promoter of Cd25, Icos, Gitr or Ctla4 together with Foxp3- or YY1-expressing vectors. Foxp3 directly transactivated promoter activities of its target genes (Fig. 8b). However, YY1 expression inhibited this transactivation by Foxp3 (Fig. 8b). Foxp3binding to its target promoters was investigated using ChIP assays in control or YY1-transduced Treg cells. Foxp3 binding to the promoters was remarkably reduced in YY1-transduced Treg cells compared with control cells (Fig. 8c), suggesting that YY1 inhibits Foxp3 binding to its target sites. YY1 directly bound to the promoters of Foxp3-target genes in YY1-transduced Treg cells (Fig. 8d,e) as well as in Tconv cells (Fig. 8f). Taken together, these data suggest that YY1 interacts with Foxp3, blocks binding of Foxp3 to its target genes and binds to the Foxp3-target genes, and that YY1 binding inhibits expression of these genes.

Figure 8: YY1 inhibits expression of Foxp3-target genes.
figure 8

(a) HEK293T cells were transfected with a Foxp3- or YY1-expression vector. Cell lysates were immunoprecipitated with an anti-Foxp3, anti-YY1 or control IgG antibody. Then, proteins were immunoblotted by an anti-Foxp3 or anti-YY1 antibody, as indicated. IP, immunoprecipitation; WB, immunoblot. (b) Transactivation activity of YY1 and Foxp3 on the Foxp3-target genes was measured by transient reporter assay. EL4 cells were transfected with CD25P-, IcosP-, GitrP- or Ctla4P-luciferase reporter construct in combination with Foxp3 or YY1 expression vector. (c,d) Binding of Foxp3 (c) and YY1-Flag (d) to the promoters of the Foxp3-target genes in control or YY1-Flag-expressing Treg cells was measured by ChIP assay. (e) Binding of YY1 to YY1-binding sites (YBS) in the promoters of the CD25, Gitr and Clta4 genes was detected by EMSA using control or YY1-expressing Treg nuclear extracts. Competition assay was performed with YY1 consensus sequence (x80). (f) Binding of YY1 to the promoters of the Foxp3-target genes in Tconv or Treg cells was measured by ChIP assay. Error bars shown in be represent s.d. Statistical significance of differences of be) were determined by Student’s t-test (n=3). *P<0.05. **P<0.01. Data are representative of three independent experiments with similar results.

Domains of YY1 critical for inhibition of Treg functions

To identify which domains of YY1 are important for interaction with other proteins, expression vectors containing YY1 deletion mutants were constructed (Fig. 9a). Protein–protein interactions between the YY1 deletion mutants and Smad3, Smad4 or Foxp3 were investigated using co-IP assays. YY1 was associated with Smad3 (Fig. 9b), Smad4 (Fig. 9c), Foxp3 (Fig. 9d) and Smad2 (Supplementary Fig. 5A). Deletion of the spacer or zinc finger 1-2 domains of YY1 caused loss of interactions with Foxp3, Smad3 and Smad4 (Fig. 9a–d, Supplementary Figs 4A–C), suggesting that these domains mediate interactions with other proteins.

Figure 9: Spacer and zinc finger 1-2 domains of YY1 are essential for inhibition of Treg differentiation.
figure 9

(a) Schematic diagram of YY1 domains. (bd) HEK293T cells were transfected with Smad3-, Smad4- or Foxp3-expression vector together with various FLAG-tagged, YY1 domain mutant expression vectors. Cell lysates were immunoprecipitated with anti-FLAG. Then, proteins were immunoblotted by an anti-Smad3 (b), anti-Smad4 (c), anti-Foxp3 (d) or anti-FLAG antibody, as indicated. IP, immunoprecipitation; WB, immunoblot. (e) Naïve CD4 T cells were transduced with a retroviral vector containing control, YY1 (full length), YY1 ΔS, YY1 ΔZ or YY1 ΔSZ, and differentiated into Treg cells for 4 days. Expression of Foxp3 was measured by flow cytometry. Numbers in the plots indicate percentage of Foxp3+ cells from GFP+ cells. (f) GFP+ cells from e were sorted, and total RNA was isolated. Relative amounts of the Foxp3 and Treg signature genes were measured by qRT–PCR. Experiments were performed three times with similar results. Error bars shown in b and f represent s.d. Statistical differences in e and f were analysed by Student’s t-test (n=3). *P<0.05. **P<0.01.

To examine whether the spacer and zinc finger 1-2 domains of YY1 play an essential role in the inhibition of Treg differentiation and function, we constructed retroviral vectors containing YY1 deletion mutants that have a deletion in spacer (YY1 ΔS) or zinc finger 1-2 domains (YY1 ΔZ), transduced them into naïve CD4 T cells, and differentiated them into Treg cells. Foxp3 levels were greatly reduced in YY1-transduced Treg cells compared with those in control Treg cells (Fig. 9e). However, all the YY1 deletion mutants failed to reduce Foxp3 expression in Treg cells (Fig. 9e). In addition, these mutants failed to decrease Treg cell signature genes regulated by Foxp3 in Treg cells (Fig. 9f). To further examine the role of YY1 deletion mutants in Foxp3-mediated target gene expression, a transient reporter assay using reporter constructs containing the promoter of Foxp3 (Foxp3P), Foxp3P-CNS1, CD25P or Ctla4P was performed in the presence of various YY1 deletion mutants. Full-length YY1 repressed the expression of Foxp3, Cd25 and Ctla4 genes mediated by Smad3D or by Foxp3 (Fig. 10). However, YY1 ΔZ failed to inhibit the transactivation of the Foxp3 gene by Smad3D, suggesting that the inhibition of Foxp3 expression is mediated by the zinc finger 1-2 domains of YY1 (Fig. 10a,b). In addition, YY1 ΔS or YY1 ΔZ failed to inhibit transactivation of Cd25 and Ctla4 mediated by Foxp3 (Fig. 10c,d). These results strongly suggest that the spacer and zinc finger 1-2 domains of YY1 are critically important for its inhibition of Smad3 and Foxp3 functions.

Figure 10: Spacer and Zinc finger domains of YY1 are essential for inhibiting transactivation activity of Smad3 or Foxp3.
figure 10

Transactivation activity of Smad3, Foxp3 or YY1 domain mutants at the promoters of the Foxp3, CD25 or Ctla4 genes was measured by transient reporter assay. EL4 cells were transfected with Foxp3 promoter-luc (a), Foxp3 promoter-CNS1-luc (b), CD25 promoter-luc (c) or Ctla4 promoter-luc (d) reporter construct in combination with Smad3D-, Foxp3- or YY1 domain mutant expression vectors. Error bars shown in ad represent s.d. Statistical differences were analysed by Student’s t-test (n=3). *P<0.05. **P<0.01. I, ionomycin; NT, no treatment; P, phorbol 12-myristate 13-acetate.

Discussion

The results of this study show that YY1 inhibits differentiation and function of Treg cells. YY1 expression is lower in Treg cells than in Tconv cells, and overexpression of YY1 reduces the expression of Foxp3 and its target genes. Furthermore, YY1 abrogates the immunosuppressive function of Treg cells both in vivo and in vitro. YY1 directly binds to the Foxp3 gene, reducing its expression, and represses chromatin remodelling of the locus. YY1 interacts with Smad3/4 and blocks their induction of Foxp3 expression. Furthermore, YY1 inhibits the induction of Foxp3-target genes by binding to the Foxp3 protein and by blocking its binding to its target loci.

As Foxp3 is the critical transcription factor for the differentiation and maintenance of Treg cells, understanding the molecular mechanisms for the regulation of Foxp3 is crucial for controlling immune homeostasis3,11,12. Although many factors have been shown to induce or stabilize Foxp3 (refs 3, 11, 12), only a few factors were shown to inhibit the expression or function of Foxp3. In some cases of diseases such as chronic infectious diseases and cancer, heightened Treg function is an obstacle for complete cure of the diseases7. In these cases, negative regulation of Foxp3 function could help to boost protective immunity against these diseases. In this study, YY1 is characterized as a new negative regulator of Foxp3 and of Treg cells.

In this study, we found that YY1 has pleiotropic functions and multiple roles in the inhibition of Treg cell development and function (summarized in Supplementary Fig. 6). First, YY1 binds directly to regulatory regions in the Foxp3 locus, which suppresses the expression of the Foxp3 gene. Similar inhibitory mechanisms of regulation of the Foxp3 gene were suggested in previous studies: GATA3 (ref. 14 and RORγt16 bind to the Foxp3 promoter, and STAT3 (ref. 15) binds to the Foxp3 CNS2, which cause a repression of the Foxp3 gene. How YY1 inhibits the Foxp3 gene after binding to the Foxp3 locus is not yet clear. One possibility is that YY1 may recruit chromatin remodelling factors to induce repressed chromatin status at the locus. YY1 interacts with many chromatin remodelling factors including the INO80 complex, histone acetyltransferases, histone deacetylases and histone methyltransferase17,18,19,35. The finding that YY1 reduced H3K4-me3 at the Foxp3 locus supports this possibility; however, the detailed mechanisms of YY1-mediated repression of the Foxp3 gene remain to be elucidated.

Second, YY1 inhibits the induction of Foxp3 expression by blocking TGF-β signalling. A previous study showed that YY1 interacts with Smad proteins to inhibit TGF-β or BMP signalling25. The present study shows that YY1 has a similar role in inhibiting Treg cell development. YY1 associates with Smad3 and Smad4 to block their binding to the Foxp3 CNS1, which is a crucial Smad-binding site for Foxp3 expression during Treg cell differentiation.

Third, YY1 inhibits Foxp3-induced expression of target genes by physically binding to and blocking Foxp3. Foxp3 is a global regulator of its target genes; Foxp3 binds to numerous target genes and induces their expression, which is essential for Treg cell differentiation and function. Previous studies have shown that Foxp3 is capable of binding several proteins24. For example, Foxp3 binds to AML1 and inhibits the production of the cytokine IL-2 (ref. 36). Foxp3 also binds to NFAT and interferes with the conformation of AP1–NFAT complexes that are essential for effector cell programmes37. Foxp3 also interacts with GATA3 (refs 24, 38) and RORγt39, and these interactions lead to inactivation of Foxp3. Our data show that YY1 binds to Foxp3 and abrogates its function. YY1-mediated inhibition of the Foxp3-target genes can be explained by two possible mechanisms. The interaction of YY1 with Foxp3 may physically interfere with Foxp3 binding to its target genes. Another possibility is that YY1 binding to the Foxp3 target gene loci may inhibit Foxp3 binding to the loci. Here, YY1 directly bound to the promoter of the Foxp3 target genes. Although the cognate YY1-binding sites are separate from the Foxp3-binding site, YY1-binding sites appear to be present in the promoters of the Foxp3 target genes, including Cd25, Icos, Ctla4 and Gitr.

Like other transcription factors interacting with Foxp3, such as RORγt, STAT3 and GATA3, YY1 is implicated in effector CD4 T-cell differentiation. We previously have shown that YY1 plays an important role in Th2-cell differentiation23. The set of transcription factors including YY1 have dual roles in CD4 T-cell differentiation: one is to stimulate a specific effector subset differentiation, and the other is to inhibit Treg-cell differentiation. Thus, the outcome of the reciprocal inhibition would be the fate decision of effector versus Treg-cell differentiation. Although most of these proteins are normally expressed exclusively with Foxp3, they may be co-expressed in certain situations such as during the course of infection. The proinflammatory response predominates at the initial phase of infection, whereas the anti-inflammatory response predominates at the later resolving phase of infection40. Reciprocal regulation of the effector-specific transcription factors and Foxp3 may determine proinflammatory versus anti-inflammatory reactions.

In conclusion, the present study illustrates that YY1 inhibits the differentiation and function of Treg cells by blocking Foxp3 expression and function. This study elucidates fundamental molecular mechanisms of Treg differentiation, and may contribute to the development of therapeutic strategies for many immune-related diseases and cancer.

Methods

Mice

Six- to eight-week-old C57BL/6 mice were purchased from Samtaco, and CD4-CRE transgenic mice were purchased from Taconic. RAG1-deficient (C57BL/6) mice, YY1 flox/flox (C57BL/6) mice, Foxp3-eGFP (C57/BL6) and Foxp3-RFP (C57/BL6) mice were purchased from Jackson Laboratory. YY1 KD mice were previously described23. All mice were maintained in the Sogang University animal facility under specific pathogen-free conditions. Experiments with live mice were approved by the Sogang University Institutional Animal Care and Use Committee.

In vitro differentiation of CD4 T cells

CD4 T cells were enriched from spleen cells from WT mice by mixing with anti-MHC class II (M5/115, cat. no. MABF33, Millipore, diluted 1/200), anti-NK1.1 (PK136, cat. no. 108712, BioLegend, diluted in 1/200) and anti-CD8 (53-6.7, cat. no. 100735, BioLegend, diluted in 1/200) antibodies, followed by depletion with a mixture of magnetic beads conjugated to anti-rat IgG (BioMag, cat. no. 84334, Polybioscience, diluted in 1/10) and anti-mouse IgG antibodies (BioMag, cat. no. 84340, diluted in 1/10). Naïve CD4 T cells were sorted based on the surface markers, CD4high, CD62Lhigh and CD44low. The cells were activated by plate-bound anti-CD3ɛ (2C11, BioLegend, 5 μg ml−1) and soluble anti-CD28 (37.51, BioLegend, 2 μg ml−1) antibodies. For neutral (Th0) differentiation, 1 × 106 naïve CD4 T cells were cultured in 5 ml of RPMI-1640 culture medium (Life Technologies) supplemented with 5% fetal bovine serum, 2-mercaptoethanol, MEM amino acids solution (Life Technologies), non-essential MEM amino acids solution (Life Technologies) and penicillin–streptomycin solution (Life Technologies) in the presence of IL-2 (1 ng ml−1). For Th1 skewing conditions, IL-12 (3.5 ng ml−1) and 11B11 (anti-IL-4, 10 μg ml−1) antibody were added to same media. For Th2 cell differentiation, IL-4 (5 ng ml−1) and XMG1.2 (anti-IFN-γ, 10 μg ml−1) antibody were added. Treg conditions comprised treatment with TGF-β (5 μg ml−1), IL-2 (1 ng ml−1), XMG1.2 antibody (10 μg ml−1) and 11B11 antibody (10 μg ml−1). After 4–5 days, the cells were used for further experiments.

EMSA

Nuclear extracts (5 μg) were incubated for 30 min on ice in binding buffer (10 mM Tris-Cl, pH 8.0, 40 mM KCl, 0.05% NP-40, 6% glycerol, 1 mM dithiothreitol (DTT), 1 μg μl−1 of poly(dI:dC)) and then 0.5 ng of 32P-labelled double-stranded oligonucleotides were added to the mixture and incubated for 30 min on ice. The oligonucleotide sequences used are described in Supplementary Table 1.

Chromatin immunoprecipitation

Cells (1 × 107) were cross-linked with 1% paraformaldehyde on ice for 30 min and quenched with 0.125 M glycine. Cells were then lysed with a buffer containing 1% SDS and sonicated at the high-power setting for 15 min using a Bioruptor sonicator (Diagenode). Cell extracts were pre-cleared with protein A/G agarose/salmon sperm DNA (Upstate) and incubated with an anti-H3K4-me3 (Millipore, 07-473), anti-H3Ac (Millipore, 06-599), anti-YY1 (Santa Cruz, sc-1703), anti-FLAG (Sigma, M2) or normal rabbit IgG or normal mouse IgG (Santa Cruz) as a negative control. Antibody-bound protein–chromatin complexes were precipitated by protein A/G agarose, washed and eluted. The chromatin was reverse cross-linked by incubating at 65 °C for 4 h, followed by protease K treatment. After clean-up, the amount of precipitated DNA was quantified by quantitative PCR using the SYBR green (Kappa Bio) method with the primers listed in Supplementary Table 2.

RNA isolation and qRT–PCR

Total RNA was isolated from naive CD4 T cells or in vitro-differentiated Th0, Th1, Th2 or Treg cells using Trizol reagent (Invitrogen). Reverse transcription (RT) was performed using Superscript II RT (Topscript). Quantitative PCRs for cDNA were performed with real-time fluorogenic 5′-nuclease PCR or SYGR green method using the 7500 Real-Time PCR System (Applied Biosystems). Relative amounts of expression were normalized by the amount of the Hprt transcript. The dual labelled probe and primer sequences used for quantitative PCR are listed in Supplementary Table 3.

Microarray analysis

The synthesis of target cRNA probes and hybridization were performed using Agilent’s Low RNA Input Linear Amplification kit (Agilent Technologies) according to the manufacturer’s instructions. Briefly, each 1 μg total RNA and T7 promoter primer mix and incubated at 65 °C for 10 min. cDNA master mix (5 × First strand buffer, 0.1 M DTT, 10 mM dNTP mix, RNase-Out and MMLV-RT) was prepared and added to the reaction mixer. The samples were incubated at 40 °C for 2 h and then the RT and double-stranded (dsDNA) synthesis was terminated by incubating at 65 °C for 15 min. The transcription master mix was prepared as the manufacturer’s protocol (4 × Transcription buffer, 0.1M DTT, NTP mix, 50% PEG, RNase-Out, Inorganic pyrophosphatase, T7-RNA polymerase and Cyanine 3/5-CTP). Transcription of dsDNA was performed by adding the transcription master mix to the dsDNA reaction samples and incubating at 40 °C for 2 h. Amplified and labelled cRNA was purified on cRNA Cleanup Module (Agilent Technologies) according to the manufacturer’s protocol. Labelled cRNA target was quantified using ND-1000 spectrophotometer (NanoDrop Technologies). After checking labelling efficiency, fragmentation of cRNA was performed by adding 10 × blocking agent and 25 × fragmentation buffer and incubating at 60 °C for 30 min. The fragmented cRNA was resuspended with 2 × hybridization buffer and directly pipetted onto assembled Agilent’s Mouse Oligo Microarray (60 K). The arrays hybridized at 65 °C for 17 h using Agilent Hybridization oven (Agilent Technologies). The hybridized microarrays were washed as the manufacturer’s washing protocol (Agilent Technologies). The hybridized images were scanned using Agilent’s DNA microarray scanner and quantified with Feature Extraction Software (Agilent Technologies). All data normalization and selection of fold-changed genes were performed using GeneSpringGX 7.3 (Agilent Technologies). Functional annotation of genes was performed according to the Gene OntologyTM Consortium (http://www.geneontology.org/index.shtml) by GeneSpringGX 7.3 (Agilent Technologies). Gene classification was based on searches done by BioCarta (http://www.biocarta.com/), GenMAPP (http://www.genmapp.org/), DAVID (http://david.abcc.ncifcrf.gov/) and Medline databases (http://www.ncbi.nlm.nih.gov/). The microarray data were deposited in GEO database (GEO accession number: GSE75052).

Immunoblot analysis

Protein or cell extracts were resolved on a 10% SDS–PAGE gel and transferred to a polyvinylidene difluoride membrane (Bio-Rad). The membrane was blocked with 5% skim milk in TBST for 1 h at room temperature. The membrane was then probed with an antibody against FLAG, Foxp3 (eBioscience), Smad2 (Cell Signaling, 5339), pSmad3 (Cell Signaling, 9520), Smad3 (Abcam, 29379), Smad4 (Cell Signaling, 9515), YY1 (Santa Cruz, sc-1703) or β-actin (Santa Cruz, sc-47778), diluted 1:100 or 1:1,000 in TBST overnight at 4 °C. An HRP-conjugated antibody against rabbit or mouse (BioLegend) diluted at 1:2,000 in 5% skim milk TBST was added for 1 h at room temperature. Target proteins were detected by enhanced chemiluminescence reaction. Images have been cropped for presentation. Full-size images are presented in Supplementary Fig. 7.

DNA pull-down assay

Nuclear extracts were isolated from HEK293T cells by sonication. Chromatin DNA was pelleted at 14,000g for 15 min at 4 °C, and the nuclear lysates in the supernatant were collected. Biotin-labelled DNA probes (1 μg) were incubated with nuclear lysate with proteinase inhibitors for 30 min at room temperature in binding buffer (10 mM Tris-Cl, pH 8.0, 50 mM KCl, 1 mM DTT, 5% glycerol, 1 μg ml−1 poly(dI:dC), 1 mg ml−1 salmon sperm DNA, 1 mg ml−1 BSA). Protein–DNA complexes were collected with streptavidin agarose (50 μl, Sigma-Aldrich). Precipitated proteins were washed five times with binding buffer and resuspended in an SDS loading buffer. Immunoblot analysis was performed as described above.

Retroviral transduction

For ectopic expression, mouse Yy1 (WT or deletion mutants) coding sequences were cloned into MIEG3 retroviral vector. A total of 1 × 106 Phoenix Eco cells were co-transfected with retroviral vector and pCL-Eco helper vector. A culture supernatant containing high titres of retrovirus was collected after 48 h of transfection. Purified naive CD4 T cells were activated under Th0 condition with plate-bound anti-CD3 (5 μg ml−1) and anti-CD28 (2 μg ml−1) for 24 h. Activated cells were then spin-infected in 1 ml of retrovirus-containing supernatant with polybrene (4 μg ml−1) at 1,500g for 90 min at 32 °C. After the spin infection, cells were incubated for 4–5 days under the Th0 or Treg condition. GFP+ cells or total cells were used for further experiments.

FACS staining

For Foxp3, cells were stained with anti-Foxp3 (eBioscience) using a Foxp3 staining kit (BioLegend). For YY1 staining, total splenocytes from YY1-eGFP mice were enriched by CD4 microbeads (Miltenyi). Tconv (CD4+CD25) or Treg (CD4+ CD25+) cells from WT mice were prepared using a CD4+CD25+ Treg isolation kit (Miltenyi). The cells were stained with an anti-YY1 (Santa Cruz sc-1703) antibody using a Foxp3 staining kit (BioLegend). For cytokine staining, cells were restimulated with 1 μM ionomycin (Sigma-Aldrich) and 10 nM phorbol myristate acetate (Sigma-Aldrich) with Golgi stop (BD Bioscience) for 4 h. Intracellular staining was performed using Cytofix/cytoperm kit (BD Bioscience).

Co-immunoprecipitation

HEK293T cells were transfected with FLAG-tagged pCMV-Yy1, pCMV-Smad3, pCMV-Smad4 and pCMV-Foxp3. Two days after transfection, cell lysates were isolated and then pre-cleared with control IgG followed by protein A/G (Santa Cruz) treatment. Pre-cleared lysates were incubated overnight at 4 °C with anti-YY1, anti-Smad3, anti-Smad4, anti-Foxp3, anti-FLAG or control IgG antibody. Then, protein A/G beads were added, followed by incubation for an additional 4 h. Immunocomplexes were extensively washed and resuspended in an SDS loading buffer. Immunoblot analysis was performed as described above.

Dual luciferase assay

EL4, a mouse lymphoma cell line, was co-transfected with a combination of CMV-Yy1, CMV-Smad3D or CMV-Foxp3 expression vectors, and pGL-Foxp3P or pGL-Foxp3 P/CNS1, pGL-Il2raP, pGL-IcosP, pGL-Ctla4P or pGL-GitrP reporter vectors. The following day, luciferase activity was measured. Transfection efficiency was normalized by dividing Firefly luciferase activity by Renilla luciferase activity.

In vitro suppression assays of YY1-transduced Treg cells

Treg cells were isolated from Foxp3-RFP knock-in mice based on RFP expression. Isolated Treg cells were transduced with control or YY-1-expressing retroviral vector as described above. After sorting of GFP+-transduced Treg cells, 1 × 105 cells were plated in 96-well plates. CD4+CD25 Tresp cells were freshly isolated from CD45.1 mice on C57BL/6 background, and were labelled with CFSE (Sigma). Tresp cells (1 × 105) were added together with anti-CD3/CD28 beads (Invitrogen) in 96-well plates. After 3 day cultures, Tresp cells were selected and analysed using FACS caliber (BD Bioscience).

Induction of inflammatory bowel disease

Naïve CD4 T (CD4+CD62hiCD45RBhi) cells from C57BL/6 mice were sorted on a FACS Aria III (BD Bioscience). Inflammatory bowel disease was induced by the adoptive transfer of 5 × 105 naïve CD4 T cells into Rag1−/− mice by retro-orbital injection. Naïve CD4 T cells (5 × 105) alone or together with control vector-transduced GFP+ Treg cells (1 × 105) or YY1-transduced GFP+ Treg cells (1 × 105) were transferred into Rag1−/− mice. Recipient mice were weighed two times per week. After 9 weeks, mice were killed, and splenocytes and CD4 T cells were counted by flow cytometry. For histological analysis, the colon was removed and fixed in 10% (vol/vol) buffered formalin solution, and sections were stained with haematoxylin and eosin.

Statistical analysis

Values are shown as the mean±standard deviation (s.d.). Statistical differences between mean values were determined by Student’s t-test. Results were considered significant when the P-value was less than 0.05.

Additional information

How to cite this article: Hwang, S. S. et al. YY1 inhibits differentiation and function of regulatory T cells by blocking Foxp3 expression and activity. Nat. Commun. 7:10789 doi: 10.1038/ncomms10789 (2016).